"Designing Growth Strategies is in our DNA"

Autism Spectrum Disorder Treatment Market Size, Share & COVID-19 Impact Analysis, By Drug Therapy (Antipsychotic Drugs, Selective Serotonin Reuptake Inhibitors, Stimulants, Sleep Medications, and Others), By Disease (Autistic Disorder, Asperger Syndrome, Pervasive Developmental Disorder, and Others), By Age Group (Children and Adults), By Distribution Channel (Hospital Pharmacies, Drugs Stores & Retail Pharmacies, and Online Pharmacies) and Regional Forecast, 2022-2029

Region : Global | Format: PDF | Report ID: FBI101207

 

KEY MARKET INSIGHTS

Play Audio Listen to Audio Version

The global autism spectrum disorder treatment market size was valued at USD 1.85 billion in 2021. The market is projected to grow from USD 1.93 billion in 2022 to USD 3.17 billion by 2029, exhibiting a CAGR of 7.4% during the forecast period. The global COVID-19 pandemic has been unprecedented and staggering, with autism spectrum disorder treatment experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. Based on our analysis, the global autism spectrum disorder therapeutics market had exhibited a rise of 8.6% in 2020 as compared to 2019.     


Autism spectrum disorder, also known as ASD, refers to a group of neurological disorders characterized by persistent deficits in social interaction and social communication and a repetitive/restricted pattern of behavior or activities. Autistic disorder, Asperger syndrome, and Pervasive Development Disorder (PDD) are the three main types of the disorder, which affect millions of people globally.


According to a 2020 report by the Centers for Disease Control & Prevention (CDC), an estimated 1 out of 54 children has been diagnosed with autism disorder in the U.S. There are a number of factors that are anticipated to contribute to the market’s growth prospects. The growing prevalence of the disease globally, coupled with rising awareness about the condition & the available options for various treatment type of different diseases are the key factors expected to drive the autism spectrum disorder therapeutics market size during the forecast period. Moreover, growing investments by key players in R&D initiatives for the launch of effective drugs to treat autistic disorders are expected to fuel the global market growth.


COVID-19 IMPACT


Robust Demand for Drugs during COVID-19 Backed by Growing Adoption of Telehealth to Push Market Growth


The unprecedented pandemic at the initial stages resulted in a shutdown of a number of companies in the healthcare industry, leading to a slowdown of manufacturing processes. Additionally, the closure of therapy centers and autistic disorder-related services resulted in the halt/postponement of therapy sessions for autistic children. However, growing anxiety levels in autistic patients and the risk of contracting COVID-19 as these fall under vulnerable groups led to the strong adoption of telehealth systems by the patient caregivers/family. This factor also increased the demand for therapeutics and other off-label prescription drugs such as antipsychotics, SSRI, and sleep medications. Furthermore, the increased usage of online channels to procure autism medications also contributed to the growth of the market during COVID.


Also, various companies such as Otsuka Pharmaceutical Co., Ltd, and Johnson & Johnson witnessed strong sales trends for the drugs for treatment of the condition. For instance, Otsuka recorded a 14.0% increase in sales for Abilify Maintena, over the FY 2019. Therefore, COVID-19 has had a positive impact on the growth of the market.


LATEST TRENDS


Request a Free sample to learn more about this report.


Increased Exploration into Enzyme Replacement Therapy (ERT) as a Novel Therapy for ASD


Autism Spectrum Disorder is a life-long disorder that affects the patient and the caregivers, family, and communities. Every child or adult with autism has different set of challenges; and many people diagnosed with autism, have additional medical conditions such as gastrointestinal (GI) distress. In the 1980s and 1990s, it was first suggested that autistic patients could not digest food proteins very well, specifically the protein casein (found in milk) and gluten (found in wheat). Many therapies were developed based on this idea, however, due to some difficulties, the therapies were discontinued, and then the enzyme replacement therapy was introduced, which is one of the most important trends witnessed in disease treatment.


Researchers around the globe believe that autism is caused by excess opioid activity in the brain, which leads to the digestive problem associated with particular proteins in food. For instance, Curemark developed a drug CM-AT that received a “Fast Track” designation from the U.S. FDA for children with autism, who have an unusually low level of chymotrypsin. This enzyme is essential for breaking down dietary protein into amino acids that the body cannot make on its own. Due to the various positive avenues, enzyme replacement therapy is proving to be a positive novel therapy for treating this disorder.


DRIVING FACTORS


Rising Prevalence of the Condition to Propel Market Growth


An increase in the prevalence of autism spectrum disorder (ASD) is positively impacting the growth of the market globally, which has led to increasing demand for clinical research for effective treatment. This can improve patient outcomes and greater accuracy for the treatment of these conditions. For instance, according to a compiled report on worldwide autism rates by Global Health Data Exchange, countries such as France and Portugal have the lowest autism rate of 0.69% and 0.71%, respectively. In contrast, most Middle Eastern countries like Qatar, United Arab Emirates, Oman, Bahrain, and Saudi Arabia have been reported to have the highest prevalence of the disease.


For instance, in 2021, the prevalence of autism in Qatar is estimated to be 1.6% and 1.0% in Saudi Arabia. This growing prevalence rate in emerging countries is also anticipated to be one of the key reasons for the market growth, due to the increased demand for effective drugs. Launches of effective drugs are further anticipated to lead to improved patient outcomes, contributing to autism spectrum disorder treatment market growth prospects.


Government Initiatives to Increase Awareness for the Disorder to Boost Market Growth


An increasing number of government initiatives like forming various foundations and sanctioning different funding for the awareness of autism in several countries is driving the market growth. Some of the government initiatives for increasing the awareness of autism across the globe include the initiatives conducted by the Saskatchewan Government.


In July 2021, the Saskatchewan Government announced that families with children diagnosed with the condition will benefit from expanded funding. From 27th July 2021, Autism Individualized funding is available for children aged 11. Children born on or before March 31, 2021, were eligible to apply for the final payment. Furthermore, in 2021-2022, USD 10.3 million was assigned to provide USD 6,000.0 annually to children who have ASD between the ages of 6 to 11 years.


Such an increasing number of initiatives for patients with the condition would eventually lead to early diagnosis of the symptoms and boost the market growth. Furthermore, demand for autism treatment drugs after diagnoses is expected to contribute to the market growth.


RESTRAINING FACTORS


Lack of Approved Drugs to Hamper Market Growth


Currently, no drug can cure autism spectrum disorder or any of its associated core symptoms despite the increase in the need for effective drugs and clinical trials for autism. Concerned with the stalling of ASD therapeutics, the International Society of CNS Clinical Trials and Methodology and the European College of Neuropsychopharmacology created an ASD working group to review and identify the challenges related to drug development.


It has been witnessed that there is a fundamental weakness in methods, knowledge gaps, and conceptual models in clinical translation research. The agencies and the key companies are currently working on many molecules like Vasopressin 1A antagonist, bumetanide, and oxytocin receptor agonist, which have diverse mechanisms. In the era of targeted treatments, there has been no conclusive evidence supporting any drug's efficacy for the treatment of the condition core symptoms despite multiple attempts. Therefore, posing a challenge for treatment development, thus, hampers the market growth.


SEGMENTATION


By Drug Therapy Analysis


Stimulants to Emerge as the Dominant Segment during 2022-2029


Based on drug therapy, the global market is segmented into antipsychotic drugs, SSRIs/antidepressants, stimulants, sleep medications, and others.


The stimulants segment held a dominating market share in 2021 in the market due to increased focus and decreased hyperactivity in people with autism and is projected to expand at a considerably high CAGR during the forecast period. Stimulants particularly contribute to a substantial increase in the core symptoms of autism.


The SSRIs/antidepressants segment held the second dominant share, as it is the most commonly prescribed class of drug to autistic people. SSRIs like fluoxetine and sertraline help reduce the intensity and frequency of autism-related behaviors like repetitive actions, anxiety, irritability, tantrums, and aggressive actions. This segment is expected to expand at a considerably high CAGR during the forecast period.


The antipsychotic drugs segment is expected to strongly dominate the market during the forecast period as currently, the only two FDA approval (risperidone and aripiprazole) available to treat the irritability associated with the disorder belong to this segment.


The sleep medications segment is expected to account for a substantial proportion of the market as many patients on the autism spectrum suffer from sleep disturbances. The others segment are expected to account for limited share of the market during the forecast period.


By Disease Analysis


To know how our report can help streamline your business, Speak to Analyst


Increased Prevalence of Autistic Disorder to Lead to Segment’s Dominance


Based on disease, the global market is segmented into autistic disorder, Asperger syndrome, pervasive developmental disorder, and others.


The autistic disorder segment held a dominant market share in the year 2021 owing to the high prevalence of this disease type. The segment held a 54.3% market share in 2021 and is projected to expand at a considerably high CAGR during the forecast period.


According to Pfizer’s report, 1 of every 6 to 8-year-old children are affected by autistic disorder. Therefore, the demand for effective treatment availability is the need of the hour. Hence, pharmaceutical companies are striving to get approvals for products for the management of the disorder and reducing the disease burden on the industry.


The pervasive developmental disorder (PDD) registered a substantial share in 2021 and is expected to exhibit a swift growth rate during the studied period. As autism includes a diverse group of medical conditions, one includes difficulty in socialization and communication skills. These symptoms have been found common in patients as early as infancy. Therefore, product sales for PDD are anticipated to increase during the forecast period. The Asperger syndrome segment is expected to be account as the third largest segment during the forecast period.


By Age Group Analysis


Children Segment to Grow at Faster Pace during the forecast period of 2022-2029


The global market can be segmented into children and adults based on the age group.


The adult segment held a significant market share in the global market of 2021, owing to the growing number of service providers offering a wide range of cost-effective therapies. Furthermore, an augmented prevalence of autism in adult patients is projected to favor segmental growth


During the forecast period compared to the adult segment, the children segment is estimated to expand at a relatively higher CAGR in the forecast period owing to the rise in the diagnosis of the condition at an early age. For instance, according to an article published in HealthLine Media, most children with autism are diagnosed after three. In contrast, it can be diagnosed as early as 18 months of age in some cases.


By Distribution Channel Analysis


Higher Procurement of Therapeutics through Hospital Pharmacies Enables Dominance of Segment


Based on the distribution channel, the global market can be segmented into hospital pharmacies, drugs stores & retail pharmacies, and online pharmacies.


The hospital pharmacies held the dominant share of the global market in 2021, which is attributable to the majority of the therapeutics that can only be prescribed after thorough examinations by trained medical professionals at these institutions, and hence is expected to favor the segmental growth.


The drugs stores & retail pharmacies segment held the second-largest dominant market stake in 2021 and is expected to expand during the forecast period due to the increase in settings usage for procurement of drug refills.


The online pharmacies segment is projected to expand comparatively higher CAGR during the forecast period as most developed countries like the U.S. have well-established digital platforms. Furthermore, during COVID-19, these institutions increased the adoption to obtain prescription medications


REGIONAL INSIGHTS


North America Autism Spectrum Disorder Treatment Market 2021 (USD Billion)

To get more information on the regional analysis of this market, Request a Free sample


Based on the region, the market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.


The North America market size stood at USD 1.08 billion in 2021. The increasing prevalence of autism disorder across the U.S., coupled with the growing adoption and uptake of therapies are attributable to the region’s dominance. For instance, according to the John Hopkins report published in 2020, the autism prevalence in the U.S. has been tripled since 2000 from 0.67 to 1.85%. Moreover, the launch of several products by companies across the U.S. & Canada and strong government support contribute to the region's growth. For instance, in April 2019, the Government of Canada announced funding for a community-based project through Autism Spectrum Disorder Strategic Fund. This project has been initiated to provide opportunities for Canadians living with autism disorder. These factors have contributed to the region’s dominance.


Increasing awareness and screening, access to aid, and broadened diagnostic criteria have made Europe the second largest region in the market. Further, higher product sales o are anticipated to boost the market in the region during the forecast period.


Asia Pacific is projected to grow with the highest CAGR owing to the rising demand for effective treatment. The development of healthcare infrastructure to fulfill the need for well-equipped healthcare institutions such as hospitals for patients is also contributing to the growth of this region.


In regions such as Latin America and the Middle East & Africa, a lower rate of reported autism disorders and lack of product approvals has resulted in a slower growth rate than other regions.


KEY INDUSTRY PLAYERS


Continuous R&D Initiatives and Strategic Acquisitions by Key Players to Surge Sales Growth


The competitive landscape reflects a competitive scenario with the presence of a number of companies with diverse product portfolio. Key players in developed countries and growing investments in the research sector to develop innovative therapeutics are likely to dominate the competition scenario during the forecast period. Players engaged in drug therapy in the global market with considerable market share include Otsuka Holdings Co. Ltd., H. Lundbeck A/S, Janssen Pharmaceuticals, Inc., and Sanofi. Some of the other key players include Alembic Pharmaceuticals Limited, Teva Pharmaceutical Industries Ltd., and Aurobindo Pharma. These players specialize in the manufacturing of generic versions of the various drugs to treat the condition.


LIST OF KEY COMPANIES PROFILED:



  • Curemark, LLC (Rye, U.S.)

  • Alembic Pharmaceuticals Limited (Vadodara, India)

  • Yamo Pharmaceuticals (New York, U.S.)

  • PaxMedica (Woodcliff Lake, U.S.)

  • F. Hoffmann-La Roche Ltd (Basel, Switzerland)

  • Aurobindo Pharma Ltd. (Hyderabad, India)

  • Otsuka Holdings Co. Ltd. (Tokyo, Japan)

  • Janssen Pharmaceuticals, Inc. (Titusville, New Jersey)

  • Teva Pharmaceutical Industries Ltd. (Tel Aviv, Israel)

  • H. Lundbeck A/S (Copenhagen, Denmark)


KEY INDUSTRY DEVELOPMENTS:



  • December, 2021: F. Hoffmann-La Roche Ltd drug pipeline candidate of RO7017773 was in an ongoing trial phase 2 trial to investigate the efficacy, safety, and tolerability in participants aged 15-45 years with autism spectrum disorder (ASD). The company plans for a regulatory filing in 2024.

  • October, 2021: Axial Therapeutics announced that the company received clearance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for their lead candidate named AB-2004, which is a gut-targeted, molecular therapeutic being studied for the treatment of irritability associated with ASD.


REPORT COVERAGE


An Infographic Representation of Autism Spectrum Disorder Therapeutics Market

To get information on various segments, share your queries with us



The global autism spectrum disorder treatment market research report provides a detailed analysis of the market. It focuses on key aspects such as leading companies, product type, and leading segments of the type and treatment. Furthermore, it offers insights into the market trends and highlights key industry developments, pipeline analysis of therapeutics, impact of the COVID-19 on the market, regulatory and reimbursement scenario, and prevalence of autism spectrum disorder in key countries. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the developed market in recent years.


Report Scope & Segmentation




















































  ATTRIBUTE



  DETAILS



Study Period



2018-2029



Base Year



2021



Estimated Year



2022



Forecast Period



2022-2029



Historical Period



2018-2020



Unit



Value (USD billion)



Segmentation



By Drug Therapy



  • Antipsychotic Drugs

  • SSRIs/Antidepressants

  • Stimulants

  • Sleep Medications

  • Others  



By Disease



  • Autistic Disorder

  • Asperger's Syndrome

  • Pervasive Developmental Disorder (PDD)

  • Others



By Age Group



  • Children

  • Adults



 



By Distribution Channel



  • Hospital Pharmacies

  • Drug Stores & Retail Pharmacies

  • Online Pharmacies



 



By Geography



  • North America (By Drug Therapy, By Disease, By Age Group, By Distribution Channel, and By Country)

    • U.S. (By Disease)

    • Canada (By Disease)





  • Europe (By Drug Therapy, By Disease, By Age Group, By Distribution Channel, and By Country)


    • U.K. (By Disease)

    • Germany (By Disease)

    • France (By Disease)

    • Italy (By Disease)

    • Spain (By Disease)

    • Scandinavia (By Disease)

    • Rest of Europe (By Disease)


  • Asia Pacific (By Drug Therapy, By Disease, By Age Group, By Distribution Channel, and By Country)


    • China (By Disease)

    • Japan (By Disease)

    • India (By Disease)

    • Australia (By Disease)

    • Southeast Asia (By Disease)

    • Rest of Asia Pacific (By Disease)


  • Latin America (By Drug Therapy, By Disease, By Age Group, By Distribution Channel, and By Country)





    • Brazil (By Disease)

    • Mexico (By Disease)

    • Rest of Latin America (By Disease)





  • The Middle East & Africa (By Drug Therapy, By Disease, By Age Group, By Distribution Channel, and By Country)


    • GCC Countries (By Disease)

    • South Africa (By Disease)

    • Rest of the Middle East & Africa (By Disease)




Frequently Asked Questions

Fortune Business Insights says that the global market size was USD 1.85 billion in 2021 and is projected to reach USD 3.17 billion by 2029.

In 2021, the North American market size stood at USD 1.08 billion.

Registering a CAGR of 7.4%, the market will exhibit significant growth in the forecast period (2022-2029).

Among the drug therapy segment, the stimulants segment is expected to lead this market during the forecast period.

The rapidly growing incidence of the condition and increased initiatives for the fast-track product approvals for novel therapeutics are the major key factors that are likely to drive the market in the forthcoming years.

Otsuka Holdings Co. Ltd., and Janssen Pharmaceuticals, Inc. are some of the key players in the global market.

North America dominated the market in terms of share in 2021.

Growing patient pool, increased incidence of the condition, and increased initiatives for the launches of effective therapeutics are expected to drive the adoption.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts

Speak to an Expert
Autism Spectrum Disorder Therapeutics Market Size, Share and Global Industry Trend Forecast till 2026
  • Mar, 2022
  • 2021
  • 2018-2020
  • 162

    CHOOSE LICENSE TYPE

  • $4850
    $5850
    $7850
    Buy Now

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X